The FDA’s decision marks J&J's Spravato as the first monotherapy for adults with treatment-resistant depression.
Hosted on MSN44m
FDA Clears Spravato For Monotherapy Depression TreatmentsThe Food and Drug Administration has approved Johnson & Johnson's nasal spray as a standalone treatment for severe forms of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback